Startup launches with $245 million for twice yearly asthma treatment

A new biotech has raised $245 million to test a new asthma medication that could compete with one sold by Amgen and AstraZeneca.

The startup, Aiolos Therapeutics, was founded by former Genentech colleagues Khurem Farooq and Tony Adamis after they stumbled upon a drug being developed by Chinese pharma company Jiangsu Hengrui Pharmaceuticals Co., Ltd. The two men believed there was an unmet need in asthma, and in Jiangsu’s drug, a potential game-changer.

The experimental medication, AIO-001, is similar to Amgen and AstraZeneca’s new product Tezspire: Both work by inhibiting the thymic stromal lymphopoietin, or TSLP, which is over-expressed by people with asthma and causes airway inflammation. (Another startup, Upstream Bio, announced Tuesday that its subcutaneous TSLP inhibitor is also showing promise in a Phase 1 trial.)

Get unlimited access to award-winning journalism and exclusive events.

Combined General Meeting of June 24, 2024 – Biotech Investments

Biophytis / Key word(s): AGM/EGM/AGM/EGM Combined General Meeting of June 24, 2024 07-Jun-2024 / 07:39 CET/CEST Combined General Meeting of June 24, 2024 Paris

June 8, 2024

New study links cellular health to well-being of dementia caregivers

It’s no secret that the caregivers of spouses with memory impairment face enormous amounts of stress.

July 18, 2024

Intersectional disparities in performance assessment of emergency medicine residents

Intersectional ethnoracial disparities in emergency medicine (EM) resident assessments.

September 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.